FDA Brief

Warning letters Drugs

FDA warning letter to

Derma Solution

High riskIssued Nov 3, 2025Posted Nov 5, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Derma Solution for selling unapproved, misbranded injectable Botulax botulinum toxin drugs online to U.S. consumers.

What happened

FDA reviewed the website www.derma-solution.com and found it offered injectable botulinum toxin type A products marketed as “Botulax 300 Units” and “Botulax 300.” FDA said these are unapproved new drugs without an FDA-approved application and that their labeling lacks adequate directions for use. FDA did not conduct an inspection; this was a website review.

What FDA found

  1. The website offers Botulax botulinum toxin drugs without an FDA-approved application, so they are unapproved new drugs.

    FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  2. Botulax is a new drug because it is not generally recognized as safe and effective for its labeled uses.

    FD&C Act § 201(p) [21 U.S.C. § 321(p)]
  3. The drug labeling does not give adequate directions for safe use by a layperson.

    FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. The drugs are not exempt from adequate-directions labeling because they are not approved in the U.S.

    21 CFR 201.115(a)
  5. Offering these drugs for sale causes misbranded drugs to enter interstate commerce.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]
  6. The products are prescription drugs that cannot be used safely without a licensed practitioner’s supervision.

    FD&C Act § 503(b)(1) [21 U.S.C. § 353(b)(1)]

What FDA wants

FDA asks Derma Solution to stop offering unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days with the specific corrective steps taken and related documentation.

Who should pay attention

  • online sellers of aesthetic or prescription injectables
  • clinics and med spas buying botulinum toxin products
  • businesses or consumers sourcing unapproved Botox alternatives online

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk